In an analysis comparing two different drug combinations, namely sulfonylureas + metformin and DPP4-inhibitors + metformin, the addition of sulfonylureas to metformin demonstrated a higher risk of hypoglycemia and weight gain, indicating that DPP-4 inhibitors may be more suitable than sulfonylureas as adjunctive therapy to metformin for poorly controlled T2D patients (75, 97). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.